Life Science

TXB2 is released in substantial quantities from aggregating platelets and metabolized during circulation to 11-dehydro TXB2 and 2,3-dinor TXB2.{1410} In rats and rabbits, 2,3-dinor TXB1 has been identified as another urinary metabolite of TXB2.

An endogenous CB neurotransmitter that binds to both CB1 and CB2 receptors.

An endogenous CB neurotransmitter that binds to both CB1 and CB2 receptors.

An endogenous CB neurotransmitter that binds to both CB1 and CB2 receptors.

An intertnal standard for the quantification of 2,3-dinor TXB2 by GC- or LC-MS.

An intertnal standard for the quantification of 2,3-dinor TXB2 by GC- or LC-MS.

An intertnal standard for the quantification of 2,3-dinor TXB2 by GC- or LC-MS.

2,3-dinor-6-keto PGF1&alpha is the &beta-oxidation product of 6-keto PGF1&alpha and the major urinary metabolite of PGI2 in humans. 2,3-dinor-6-keto PGF1&alpha makes up 23% of the recovered radioactivity in urine after administration of labeled

2,3-dinor-6-keto PGF1&alpha is the &beta-oxidation product of 6-keto PGF1&alpha and the major urinary metabolite of PGI2 in humans. 2,3-dinor-6-keto PGF1&alpha makes up 23% of the recovered radioactivity in urine after administration of labeled

2,3-dinor-6-keto PGF1&alpha is the &beta-oxidation product of 6-keto PGF1&alpha and the major urinary metabolite of PGI2 in humans. 2,3-dinor-6-keto PGF1&alpha makes up 23% of the recovered radioactivity in urine after administration of labeled

2,3-dinor-6-keto PGF1&alpha is the &beta-oxidation product of 6-keto PGF1&alpha and the major urinary metabolite of PGI2 in humans. 2,3-dinor-6-keto PGF1&alpha makes up 23% of the recovered radioactivity in urine after administration of labeled

An internal standard for the quantification of 2,3-dinor-6-keto PGF1&alpha by GC- or LC-MS.